BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 9178834)

  • 1. Purine analogs in the treatment of chronic lymphocytic leukemia.
    Pott C; Hiddemann W
    Leukemia; 1997 Apr; 11 Suppl 2():S25-8. PubMed ID: 9178834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
    Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
    Bergmann L
    Leukemia; 1997 Apr; 11 Suppl 2():S29-34. PubMed ID: 9178835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
    Nabhan C; Gartenhaus RB; Tallman MS
    Leuk Res; 2004 May; 28(5):429-42. PubMed ID: 15068894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
    Mulligan SP; Karlsson K; Strömberg M; Jønsson V; Gill D; Hammerström J; Hertzberg M; McLennan R; Uggla B; Norman J; Wallvik J; Sundström G; Johansson H; Brandberg Y; Liliemark J; Juliusson G;
    Leuk Lymphoma; 2014 Dec; 55(12):2769-77. PubMed ID: 24524339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
    Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
    Tallman MS; Hakimian D
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):23-7. PubMed ID: 8714613
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.
    Cheson BD
    Semin Hematol; 1998 Jul; 35(3 Suppl 3):14-21. PubMed ID: 9685175
    [No Abstract]   [Full Text] [Related]  

  • 12. Is there a place for 2-CDA in the treatment of B-CLL?
    Mitterbauer M; Hilgenfeld E; Wilfing A; Jäger U; Knauf WU
    Leukemia; 1997 Apr; 11 Suppl 2():S35-7. PubMed ID: 9178836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of chronic lymphatic leukemia].
    Adam Z; Vorlícek J; Hejlová N
    Vnitr Lek; 1996 Aug; 42(8):573-8. PubMed ID: 8967031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
    Robak T; Kasznicki M
    Leukemia; 2002 Jun; 16(6):1015-27. PubMed ID: 12040433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
    Schirmer M; Michlmayr G; Geisen F; Konwalinka G
    Leukemia; 1996 Jul; 10(7):1253-4. PubMed ID: 8684013
    [No Abstract]   [Full Text] [Related]  

  • 16. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
    O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
    N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
    J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New purine analogues for the treatment of chronic B-cell malignancies.
    Gribbin TE
    Henry Ford Hosp Med J; 1991; 39(2):98-102. PubMed ID: 1679757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.